RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos

Ultragenyx shares rose after Genglycos received FDA accelerated approval, becoming the first treatment targeting the underlying cause of GSDIa. The approval expands Ultragenyx’s rare-disease portfolio and is a meaningful regulatory milestone that should support future commercialization prospects.

Analysis

Ultragenyx shares rose after Genglycos received FDA accelerated approval, becoming the first treatment targeting the underlying cause of GSDIa. The approval expands Ultragenyx’s rare-disease portfolio and is a meaningful regulatory milestone that should support future commercialization prospects.